Clinical trial
Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma
NCT00017316 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00017316 |
|---|---|
| Title | Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma |
| Official title | A Phase II, Pharmacologic and Biologic Study of Escalating Doses of Thalidomide (NSC #66847) Administered Orally Once a Day in Combination With a Fixed Dose of SU5416 (NSC #696819) in Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | semaxanib, thalidomide |
| Enrollment | 35 |
| Start date | Mar 1, 2001 |
| Primary completion | Sep 1, 2003 |
| First posted | Jun 12, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: